Hanmi Pharmaceutical Signs 1.7 Trillion Won Technology Export Deal with Eli Lilly... Expectation of Earnings Surprise

Securities analysts expect Hanmi Pharmaceutical's earnings to significantly improve this year due to a technology export contract for 'Sonpegluglutide' with US pharmaceutical company Eli Lilly. The large contract fee inflow is expected to boost short-term earnings and serve as an opportunity for long-term re-evaluation of the new drug's value.

Get the next 8/10 catalyst

Telegram alerts when our AI scores a story 8+/10 (~1-3 per day, no spam). Verified 30d hit rate 50.0%.

Join Telegram channel or scan with phone →